Korro Bio, Inc. Variable Lease, Cost
Korro Bio, Inc. (KRRO) reported Variable Lease, Cost of $493.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-08-06
- Korro Bio, Inc. variable lease, cost for the quarter ending 2026-06-30 was $493.00K, a 16.55% increase year-over-year.
- Korro Bio, Inc. variable lease, cost for the quarter ending 2026-03-31 was $518.00K, a 7.02% increase year-over-year.
- Korro Bio, Inc. variable lease, cost for the quarter ending 2025-12-31 was $417.00K, a 35.83% increase year-over-year.
- Korro Bio, Inc. variable lease, cost for the quarter ending 2025-09-30 was $417.00K, a 11.46% decline year-over-year.
- Korro Bio, Inc. variable lease, cost for fiscal 2025 was $1.74M, a 8.61% increase from fiscal 2024.
- Korro Bio, Inc. variable lease, cost for fiscal 2024 was $1.60M, a 32.29% increase from fiscal 2023.
- Korro Bio, Inc. variable lease, cost for fiscal 2023 was $1.21M, a 65.44% increase from fiscal 2022.
- Korro Bio, Inc. variable lease, cost for fiscal 2022 was $732.00K.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $493.00K 10-Q · filed 2026-08-06 | $1.01M 10-Q · filed 2026-08-06 | $1.43M derived: sum of 3 quarters · filed 2026-08-06 | $1.84M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $518.00K 10-Q · filed 2026-05-07 | $935.00K derived: sum of 2 quarters · filed 2026-05-07 | $1.35M derived: sum of 3 quarters · filed 2026-05-07 | $1.77M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $417.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $834.00K derived: sum of 2 quarters · filed 2026-03-12 | $1.26M derived: sum of 3 quarters · filed 2026-08-06 | $1.74M 10-K · filed 2026-03-12 |
| 2025-09-30 | $417.00K 10-Q · filed 2025-11-12 | $840.00K derived: sum of 2 quarters · filed 2026-08-06 | $1.32M 10-Q · filed 2025-11-12 | $1.63M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $423.00K 10-Q · filed 2026-08-06 | $907.00K 10-Q · filed 2026-08-06 | $1.21M derived: sum of 3 quarters · filed 2026-08-06 | $1.69M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $484.00K 10-Q · filed 2026-05-07 | $791.00K derived: sum of 2 quarters · filed 2026-05-07 | $1.26M derived: sum of 3 quarters · filed 2026-05-07 | $1.73M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $307.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $778.00K derived: sum of 2 quarters · filed 2026-03-12 | $1.24M derived: sum of 3 quarters · filed 2026-03-12 | $1.60M 10-K · filed 2026-03-12 |
| 2024-09-30 | $471.00K 10-Q · filed 2025-11-12 | $937.00K derived: sum of 2 quarters · filed 2025-11-12 | $1.29M 10-Q · filed 2025-11-12 | $1.76M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $466.00K 10-Q · filed 2025-08-12 | $825.00K 10-Q · filed 2025-08-12 | $1.29M derived: sum of 3 quarters · filed 2025-08-12 | $1.55M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $359.00K 10-Q · filed 2025-05-07 | $828.00K derived: sum of 2 quarters · filed 2025-05-07 | $1.08M derived: sum of 3 quarters · filed 2025-05-07 | $1.31M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $469.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $722.00K derived: sum of 2 quarters · filed 2025-03-18 | $953.00K derived: sum of 3 quarters · filed 2025-03-18 | $1.21M 10-K · filed 2025-03-18 |
| 2023-09-30 | $253.00K 10-Q · filed 2024-11-12 | $484.00K derived: sum of 2 quarters · filed 2024-11-12 | $742.00K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $231.00K 10-Q · filed 2024-08-13 | $489.00K 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | $258.00K 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | $732.00K 10-K · filed 2024-03-26 | |||
| 2020-12-31 | $182.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | $312.00K derived: sum of 2 quarters · filed 2021-03-29 | $418.00K derived: sum of 3 quarters · filed 2021-03-29 | $510.00K 10-K · filed 2021-03-29 |
| 2020-09-30 | $130.00K 10-Q · filed 2020-11-16 | $236.00K derived: sum of 2 quarters · filed 2020-11-16 | $328.00K 10-Q · filed 2020-11-16 | |
| 2020-06-30 | $106.00K 10-Q · filed 2020-08-12 | $199.00K 10-Q · filed 2020-08-12 | ||
| 2020-03-31 | $93.00K 10-Q · filed 2020-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |